|
GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. The London-based pharmaceuticals company said the shot was previously authorised only for adults over 60, and those aged 50 to 59 years at higher risk, but the updated decision enables rollout across the full adult population in the EU. RSV is a virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year. GSK noted that around 158,000 adults are hospitalised each year in the EU with RSV-related illness, with outcomes often more severe than in children due to under-diagnosis and higher complication rates. Sanjay Gurunathan, head of Vaccines & Infectious Diseases R&D at GSK, said the approval ‘helps protect all adults aged 18 and older in Europe against RSV’. Arexvy remains approved in more than 65 countries for adults over 60, and in over 60 countries including the US and Japan for adults aged 50 to 59 at increased risk. GSK is seeking expanded indications in other geographies, including the US and Japan. Shares in GSK rose 0.1% at 1,802.00 pence each in London on Monday morning. The wider FTSE 100 was up 0.2%. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
